Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.70 |
| ▸ | BRAF | P15056 | 10/20 | 0.69 |
| ▸ | CSF1R | P07333 | 4/20 | 0.67 |
| ▸ | KIT | P10721 | 3/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6781371 | 0.86 | MAPK14 (0.76) | POLBMAPK14MAPT | |
| SCHEMBL13561150 | 0.85 | MAPT (0.68) | POLBMAPT | |
| SCHEMBL6487458 | 0.85 | MAPK14 (0.75) | POLBMAPK14BRAFMAPTRAF1 | |
| SCHEMBL6787334 | 0.84 | MAPK14 (0.74) | POLBMAPK14BRAFMAPTRAF1 | |
| SCHEMBL6478248 | 0.84 | MAPK14 (0.74) | POLBMAPK14BRAFMAPTRAF1 | |
| SCHEMBL6777518 | 0.84 | POLB (0.74) | POLBMAPK14MAPT | |
| SCHEMBL6486525 | 0.82 | MAPK14 (0.68) | POLBMAPK14MAPT | |
| SCHEMBL19073209 | 0.82 | BRAF (0.73) | MAPK14BRAFCSF1RKITGAA | |
| SCHEMBL6781511 | 0.82 | MAPK14 (1.00) | POLBMAPK14BRAFMAPTRAF1 | |
| SCHEMBL6782336 | 0.82 | MAPK14 (1.00) | POLBMAPK14BRAFMAPTRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| CN-1271279-A | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LTD (GB) | 2000-10-25 | — | — | CN | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | POLB 3394/4885MAPK14 965/4885BRAF 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.